Previous 10 | Next 10 |
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public of...
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced that it intends to offer and sell, subje...
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) g...
"Arguing with anonymous strangers on the Internet is a sucker's game because they almost always turn out to be-or to be indistinguishable from-self-righteous sixteen-year-olds possessing infinite amounts of free time ." - Neal Stephenson, Cryptonomicon Investor sentiment and the overall m...
Stemline Therapeutics, Inc. (STML) Q2 2019 Earnings Conference Call August 02, 2019, 08:00 ET Company Participants Kenneth Hoberman - COO & Corporate Secretary Ivan Bergstein - Founder, President, CEO & Chairman Robert Francomano - SVP & Global Head, Commercial Davi...
Stemline Therapeutics ( STML ) Q2 results : Elzonris sales: $13M. More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Stemline Therapeutics (NASDAQ: STML ): Q2 GAAP EPS of -$0.42 beats by $0.14 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Net revenue for ELZONRIS® was $13.0 million for the second quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on...
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on F...
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting, highlights recent clinical and regu...
News, Short Squeeze, Breakout and More Instantly...
Stemline Therapeutics Inc. Company Name:
STML Stock Symbol:
NASDAQ Market:
Stemline Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) r...
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. That has intrepid investors wondering if their recent gains could be the beginning of something much larger. Data source: Yahoo! Finance. It isn't unusual to see small-cap...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...